CA2329140A1 - Procedes et moyens de surveillance de therapie antiretrovirale des inhibiteurs de transcriptase inverse des non-nucleosides - Google Patents

Procedes et moyens de surveillance de therapie antiretrovirale des inhibiteurs de transcriptase inverse des non-nucleosides Download PDF

Info

Publication number
CA2329140A1
CA2329140A1 CA002329140A CA2329140A CA2329140A1 CA 2329140 A1 CA2329140 A1 CA 2329140A1 CA 002329140 A CA002329140 A CA 002329140A CA 2329140 A CA2329140 A CA 2329140A CA 2329140 A1 CA2329140 A1 CA 2329140A1
Authority
CA
Canada
Prior art keywords
mutation
hiv
codon
patient
susceptibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002329140A
Other languages
English (en)
Inventor
Jeannette Whitcomb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2329140A1 publication Critical patent/CA2329140A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des tests de susceptibilité et de résistance aux médicaments antiviraux pour la recherche de posologies médicamenteuses convenant au traitement de l'infection par le VIH et au traitement du SIDA. L'invention concerne également des moyens et des procédés permettant de faire un suivi clinique de l'évolution de l'infection par le VIH et sa réponse à la thérapie antirétrovirale, et plus particulièrement la thérapie antirétrovirale des inhibiteurs de transcriptase inverse des non-nucléosides par utilisation d'essais de susceptibilité phénotypiques ou d'essais génotypiques.
CA002329140A 1998-05-26 1999-05-26 Procedes et moyens de surveillance de therapie antiretrovirale des inhibiteurs de transcriptase inverse des non-nucleosides Abandoned CA2329140A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8514898A 1998-05-26 1998-05-26
US12409099P 1999-03-12 1999-03-12
US60/124,090 1999-03-12
US09/085,148 1999-03-12
PCT/US1999/011629 WO1999061658A1 (fr) 1998-05-26 1999-05-26 Procedes et moyens de surveillance de therapie antiretrovirale des inhibiteurs de transcriptase inverse des non-nucleosides

Publications (1)

Publication Number Publication Date
CA2329140A1 true CA2329140A1 (fr) 1999-12-02

Family

ID=26772353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002329140A Abandoned CA2329140A1 (fr) 1998-05-26 1999-05-26 Procedes et moyens de surveillance de therapie antiretrovirale des inhibiteurs de transcriptase inverse des non-nucleosides

Country Status (9)

Country Link
EP (1) EP1082454A4 (fr)
JP (1) JP2002516119A (fr)
CN (2) CN1204266C (fr)
AU (1) AU772511B2 (fr)
BR (1) BR9911600A (fr)
CA (1) CA2329140A1 (fr)
MX (1) MXPA00011623A (fr)
NZ (1) NZ508834A (fr)
WO (1) WO1999061658A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
JP2003501051A (ja) 1999-05-28 2003-01-14 ビルコ・エヌ・ブイ 表現型薬物耐性と相関するｈｉｖ−１逆転写酵素における新規な変異プロフィル
US7206699B2 (en) 2000-04-18 2007-04-17 Virco N.V. Methods for measuring therapy resistance
AU2001266863A1 (en) * 2000-06-12 2001-12-24 Virologic, Inc. Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
CA2422489A1 (fr) * 2000-09-15 2002-03-21 Virologic, Inc. Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de la transcriptase inverse et decisions d'orientation therapeutique dans le traitement du vih et du sida
EP1356082A2 (fr) 2000-10-20 2003-10-29 Virco Bvba Nouveaux profils mutationnels de la transcriptase inverse du vih-1 en corr lation avec une r sistance ph notypique aux m dicaments
US7917303B2 (en) 2001-06-14 2011-03-29 Centre National de la Recherche Scientifique—CNRS Method for identifying combinations of motifs that do not mutate simultaneously in a set of viral polypeptide sequences comprising a putative drug binding site
FR2826145A1 (fr) * 2001-06-14 2002-12-20 Centre Nat Rech Scient Methode d'identification de motifs et/ou des combinaisons de motifs presentant un etat booleen de mutation prederterminee dans un ensemble de sequences et ses applications
AU2003247791A1 (en) * 2002-07-01 2004-01-19 Virologic, Inc. Compositions and methods for determining the replication capacity of a pathogenic virus
US7473524B2 (en) 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
DE60327768D1 (de) 2002-07-01 2009-07-09 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
EP4218878A1 (fr) 2011-06-28 2023-08-02 Fisher & Paykel Healthcare Limited Tube médical amélioré
CN108251500A (zh) * 2016-03-02 2018-07-06 广西医科大学 检测艾滋病治疗药物非核苷类逆转录酶抑制剂主要耐药突变位点的引物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027332A1 (fr) * 1996-01-26 1997-07-31 Innogenetics N.V. Procede de detection de mutations induites par des medicaments dans le gene de la transcriptase reverse
EP0877937B1 (fr) * 1996-01-26 2002-05-22 Virco N.V. Procede pour evaluer la chimiotherapie de patients seropositifs vih base sur la sensibilite medicamenteuse phenotypique de la souche vih du patient
DE69739645D1 (de) * 1996-01-29 2009-12-17 Monogram Biosciences Inc Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening

Also Published As

Publication number Publication date
WO1999061658A1 (fr) 1999-12-02
CN1311823A (zh) 2001-09-05
NZ508834A (en) 2004-06-25
EP1082454A1 (fr) 2001-03-14
EP1082454A4 (fr) 2005-04-13
CN1204266C (zh) 2005-06-01
CN1532290A (zh) 2004-09-29
AU4207599A (en) 1999-12-13
MXPA00011623A (es) 2002-10-17
AU772511B2 (en) 2004-04-29
JP2002516119A (ja) 2002-06-04
BR9911600A (pt) 2001-02-13

Similar Documents

Publication Publication Date Title
US20110229906A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU772511B2 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
US6653081B2 (en) Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS
CA2341679A1 (fr) Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida
CA2375905A1 (fr) Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida
US7138231B2 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
CA2422815A1 (fr) Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida
US6489098B1 (en) Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7037644B1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20050130134A1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment HIV-AIDS
WO2002099387A2 (fr) Dispositif et methodes de surveillance d'une therapie antiretrovirale inhibitrice de la protease et determination de decisions therapeutiques dans le traitement du vih/sida
ZA200210003B (en) Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids.
US7186506B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20020094522A1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2007231808A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued